Superluminal Medicines develops small-molecule therapeutics using AI, biology, and chemistry.
Superluminal Medicines has raised $65.5M in total funding. The most recent round was Series B. The last funding was announced in September 2026.
Superluminal Medicines's investors include RA Capital Management, NVIDIA, Insight Partners, Eli Lilly, Gaingels.
Superluminal Medicines is headquartered in Boston, United States.
Superluminal Medicines develops small-molecule therapeutics using AI, biology, and chemistry.
Superluminal Medicines is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Superluminal Medicines — Funding & Investors." VCBacked, September 3, 2026, https://www.vcbacked.co/company/superluminal-medicines. Accessed October 28, 2026.
VCBacked. (2026). Superluminal Medicines — Funding & Investors. Retrieved October 28, 2026, from https://www.vcbacked.co/company/superluminal-medicines
{{cite web |title=Superluminal Medicines — Funding & Investors |url=https://www.vcbacked.co/company/superluminal-medicines |website=VCBacked |access-date=October 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated